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Abstract. In recent years, chemotherapy with caffeine has 
manifested potently high efficacy against osteosarcoma, 
although adverse effects have been observed. Recently, we 
developed a novel drug delivery system (DDS) with nonionic 
vesicles prepared from Span 80 which have promising physi-
cochemical properties as an attractive possible alternative 
to commonly used liposomes. Herein, we demonstrated that 
tumor-specific caffeine-potentiated chemotherapy for murine 
osteosarcoma administered by a novel DDS with Span 80 
nano-vesicles showed significant antitumor effects as well 
as limited adverse effects. The osteosarcoma cell line, LM8, 
was transplanted into C3H/HeJ mice which then were admin-
istered therapeutic agents. Ifosfamide (IFO) was employed as 
well as caffeine as an enhancer. Span 80 vesicles containing 
IFO and/or caffeine were freshly prepared. On days 0, 2 and 
4, different combinations of the agents were administered to 
mice: IFO alone (direct i.v.), IFO vesicles (IV), IV + caffeine, 
IV + caffeine vesicles (CV), PBS alone vesicles (PV), and 
PBS alone as negative control (PBS i.v.). Then, the mice were 
sacrificed on day 7. Antitumor effects of the reagents were 
also analyzed in vitro. Moreover, fertility examination was 
performed. In vitro, a combination of IV+CV showed signifi-
cant induction of apoptosis in the early phase. Tumor volumes 
in the IV+CV group were significantly reduced compared 
with the other groups. Histological analyses showed that the 
IV and IV+CV groups had significantly lower viable tumor 
areas. The IFO direct i.v. group showed a certain grade of 
renal injury as well as marked suppression of spermato-
genesis, while the IV or IV+CV group showed no marked 
changes. The fertility test revealed that the male mice with 
IV+CV administration had normal fertility, and no malfor-
mations were detected in their progeny. This DDS model is 
of potential importance for clinical application in the therapy 
of metastatic osteosarcoma.
Introduction
At present, osteosarcoma cases with metastasis have poor 
prognosis (1,2). In recent years, caffeine-potentiated chemo-
therapy, which is chemotherapy with caffeine dosage against 
malignancies, has manifested potently high efficacy (3,4). 
Nevertheless, this method may induce side effects with 
individual diversity (5). On the other hand, there have been 
numerous developments in novel drug delivery systems (DDS) 
for drug carriers for the treatment of various diseases (6-8).
Recently, we demonstrated that nonionic vesicles prepared 
from Span 80 have promising physicochemical properties, such 
as high membrane fluidity associated with low phase transition 
temperature, which make them an attractive possible alterna-
tive to the commonly used liposomes. Span 80 is generally 
known as sorbitan monooleate, although commercial Span 80 
is a heterogeneous mixture of sorbitan mono-, di- tri, and 
tetra-esters that may contribute to high fluidity and vascular 
permeability (9-11).
A successful therapeutic model using the DDS with 
Span 80 vesicles and immobilized polysaccharides in trans-
planted colon cancer cell lines was reported (12). Herein, we 
showed that tumor-specific caffeine-potentiated chemotherapy 
for murine osteosarcoma using a novel DDS with Span 80 
nano-vesicles showed significant antitumor effects, as well as 
limited adverse effects.
Materials and methods
Antitumor agents. As therapeutic agents, ifosfamide (IFO) 
was employed as well as caffeine sodium benzoate (CSB) as an 
enhancer. IFO was obtained from Shionogi & Co. Ltd. (Osaka, 
Japan), and CSB was purchased from Maruishi Pharmaceutical 
Co. Ltd. (Osaka, Japan).
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Preparation of Span 80 nano-vesicles. Span 80 nano-vesicles, 
which contained IFO and/or caffeine, were freshly prepared 
as previously described (12). Briefly, materials for assembling 
nano-vesicles containing Span 80 (sorbitan monooleate) and 
Tween-80 [polyoxyethylene (20) sorbitan monooleate] were 
purchased from Wako Pure Chemical Industries Ltd. (Osaka, 
Japan). Cholesterol, which worked as the stabilizer of the 
membrane, was obtained from Nacalai Tesque Inc. (Kyoto, 
Japan), and polyethylene glycol, used as a stealth modifier 
against macrophages, was acquired from NOF Corp. (Tokyo, 
Japan). The solvents, normal hexane and normal saline, were 
obtained from Nacalai Tesque Inc. and Otsuka Pharmaceutical 
Factory Inc. (Naruto, Japan), respectively. All processes were 
performed under sterilized conditions.
The two-step emulsification method was employed to make 
and purify the nano-vesicles. Span 80 (190 mg) and cholesterol 
(9 mg) were dissolved in 4.5 ml of hexane by homogeniza-
tion with a micro-homogenizer, NS-310E (Microtec Co. Ltd., 
Funabashi, Japan), at 15,000 rpm for 30 sec in a sterilized 
brown glass bottle. Sequentially, 40 mg/ml of IFO and/or 
50 mg/ml of CSB, which were dissolved in 4.5 ml of normal 
saline, were dripped into the bottle of Span 80 material 
followed by homogenization for 3 min, resulting in production 
of the first emulsion. As a negative control, phosphate-buffered 
saline (PBS) was employed instead of the antitumor reagents. 
The emulsion was evaporated by a rotary vacuum evaporator, 
N-1000 (Tokyo Rikakikai Co. Ltd., Tokyo, Japan), in a vacuum 
flask on a water bath at 37˚C followed by homogenization with 
72 mg of Tween-80 and 25 mg of DSPE-020CN at 3,500 rpm 
for 5 min, which produced the second-stage emulsion. 
The second emulsion was centrifuged using an ultra-
centrifugation equipment (CP70G with RP65T rotor, Hitachi 
Koki Co. Ltd., Tokyo, Japan). After aspiration of the superna-
tant, the pellet consisting of the Span 80 vesicles was weighed 
and suspended in normal saline at a concentration of 20% w/v, 
resulting in IFO Span 80 vesicles (IV), CSB Span 80 vesicles 
(CV), and PBS alone Span 80 vesicles (PV). Immediately 
prior to administration in vivo or in vitro, these suspensions 
were extruded by a custom made extruder (EP Tech Co. Ltd., 
Ibaraki, Japan), which was equipped with a drain disk of 
100-µm thickness and a Nucleopore membrane® of 100-nm 
pore size (GE Healthcare Japan Co. Ltd., Tokyo, Japan) 
in order to control the size of the vesicles. The diameter of 
the vesicles was evaluated by the Dynamic Light Scattering 
device, DLS-6000EW (Otsuka Electronics Co. Ltd., Osaka, 
Japan). The average diameter of the vesicles was 117 nm.
In vitro evaluation of the antitumor effects of the nano-vesicles. 
The murine osteosarcoma cell line, LM8, was obtained 
from the Riken BRC Cell Bank (Tsukuba, Ibaraki, Japan). 
LM8 cells (1 ml) in Dulbecco's modified Eagle's medium 
(1x105 cells/ml suspension) were plated per well and cultured 
in 24-well culture dishes (Nunc #142475; Thermo Scientific 
Inc., Waltham, MA, USA) for a few days until the tumor cells 
were semi-confluent. Then, antitumor agents with or without 
Span 80 vesicles, consisting of PV, IV, CV, IFO (direct 
administration), CSB (direct administration), IV+CSB, 
IFO+CV and IV+CV, were administered at 100 µl/well. Cells 
were incubated with the antitumor agents at 37˚C for 1 or 2 h, 
and then the cells were harvested and evaluated for apoptosis 
and cell viability, respectively. Assessments of each condition 
were examined in triplicate.
Evaluation of cell viability. Cells were incubated with 0.4% 
trypan blue stain (Life Technologies Japan Co. Ltd., Tokyo, 
Japan) in PBS for 1 min, and then images of each well were 
captured by an inverted microscope, TMS (Nikon Instruments 
Co. Ltd., Tokyo, Japan), and a DP-25 digital camera (Olympus 
Co. Ltd., Tokyo, Japan). Non-viable cells in each image were 
evaluated by Image Pro Plus® software (Media Cybernetics 
Inc., Rockville, MD, USA) in triplicate.
Apoptosis detection by propidium iodide (PI) method. Briefly, 
cells were suspended in 500 µl of ice-cold Hank's Balanced 
Saline Solution (HBSS; Sigma-Aldrich Japan, Tokyo, Japan), 
followed by fixation with 4.5 ml of 70% EtOH at -20˚C (13). 
Fixed cells were centrifuged at 400 x g for 10 min, pellets 
were re-suspended in extraction buffer pH 7.8 which contained 
45 mM Na2HPO4 (Nacalai Tesque Inc.), 25 mM citric acid 
(Wako Pure Chemical), and 0.1% Triton X-100 (Wako Pure 
Chemical) at 37˚C for 25 min. Then, 300 µl of staining solu-
tion pH 6.8 containing 10 mM PIPES (Sigma-Aldrich Japan), 
100 mM NaCl (Nacalai Tesque Inc.), 2 mM Mg2Cl (Wako 
Pure Chemical), 0.2% Triton X-100, 50 mg/ml PI (Sigma-
Aldrich Japan), and 50 U/ml RNAse H (0.6 mg/ml, Takara 
Bio Co., Ltd., Otsu, Japan) were added to the cell suspension, 
and the fluorescence intensity was evaluated and analyzed 
in triplicate by the FACStation® and CellQuest® software 
(Becton-Dickinson, Franklin Lakes, NJ, USA).
Murine osteosarcoma therapeutic model. C3H/HeJ mice were 
employed for the therapeutic model as they are H2-matched 
to LM8 since this cell line originated from that strain of 
mouse (14). Mice were obtained from CLEA Japan Inc. (Tokyo, 
Japan) and bred at the Department of Biological Resources, 
Ehime University Integrated Center of Science. LM8 cells 
(3.0x106 cells per mice) were subcutaneously transplanted 
into 6-week-old male C3H/HeJ mice. After ~3 weeks, when 
the tumor volume reached ~500 mm3, administration of the 
therapeutic agents was initiated. A scheme of the administra-
tion protocol is presented in Fig. 1.
Combinations of the agents were administered as follows: 
PBS (i.v., sham administration), CV (0.1 mg/g BW), IFO 
(direct i.v. 0.1 mg/g BW), IV (i.v. 0.1 mg/g BW), IV+CSB, 
and IV+CV. Five to eight animals were tested in each group. 
Agents were given by tail vein injection (~50 µl) on days 0, 2 
and 4, and then the mice were sacrificed on day 7 under anes-
thesia. Tumor diameter and body weight were evaluated every 
day. After the harvest, tumor volumes and tumor weights were 
evaluated, and the entire organs were processed for histopatho-
logical analyses. All the animal experimental protocols were 
in accordance with the Guide for Animal Experimentation, 
Ehime University, and approved by the Committee for Animal 
Experimentation, Ehime University.
Histopathological analyses. Tumors and entire organs from the 
harvested mice were formalin-fixed and paraffin-embedded. 
The viability of the tumor tissue was evaluated as the area of 
viable tumor. In addition, entire organ tissue sections stained 
with hematoxylin and eosin, periodic acid-Schiff (PAS), and 
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Elastica-Goldner were screened by a skilled pathologist to 
determine the adverse effects.
Fertility test. A fertility test was performed as follows. 
Three male C3H/HeJ mice in each group that were adminis-
tered IFO, IV or IV+CV were cross-mated with 6-week-old 
female C3H/HeJ mice, and the fertility of each animal was 
evaluated.
Statistical analyses. Body weight, tumor volume, and viability 
of the tumor at the maximum sections were statistically 
compared among the different groups with the Student's t-test, 
using GraphPad Prism® software (GraphPad Software Inc., 
La Jolla, CA, USA).
Results
Antitumor effects in vitro. In vitro analyses showed that 
cultured LM8 mouse osteosarcoma cells treated with IV+CV 
manifested almost complete cell death by the trypan blue stain 
assay, while PBS, CSB, PV and CV showed almost no cell 
death. IFO resulted in 13%, IV resulted in  28%, and IFO+CV 
resulted in 75% cell death (Fig. 2 and Table I).
Apoptosis analyses in vitro. By PI analysis, almost all the 
cells treated with IV+CV underwent cell death by apoptosis. 
In contrast, PBS, CSB, PN and CV induced very limited cell 
death, whereas IFO and IV induced apoptosis or necrosis in 
a small population (8.8-10.2%), and IFO+CSB and IV+CSB 
increased the cell death effect to approximately a quarter to 
one-third of the population (Fig. 3, Table II).
Antitumor effects in vivo. The body weights were not 
significantly different among the different groups. The tumor 
volumes in the IV+CV group were significantly reduced as 
compared to those of the control groups (PBS and CV), and 
showed a tendency towards a decrease compared with the PV 
and IFO direct i.v. groups on days 5-7 (Fig. 4).
Figure 1. The in vivo therapeutic model. Administration of the antitumor agents was initiated when the tumor volume reached ~500 mm3 (day 0), and continued 
on days 2 and 4, and the mice were sacrificed on day 7.
Figure 2. Representative photomicrographs of the trypan blue-stained LM8 cells after a 2-h incubation with antitumor agents: (A) PV, (B) CV, (C) IFO, (D) 
IV, (E) IFO+CV and (F) IV+CV.
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The histopathological analyses of the tumors demon-
strated that IFO, IV, IV+CSB, and IV+CV groups showed 
significantly larger non-viable tumor areas as compared 
to the controls. In addition, the IV+CV group manifested 
significantly greater necrotic areas compared with the IFO 
and IV groups (Fig. 5).
Histopathological analyses for adverse effects in vivo. To 
clarify whether the Span 80 vesicles can prevent adverse 
effects induced by chemotherapeutic agents, histopathological 
examination of the entire organs was performed. Marked 
differences were noted in the kidney and testis. In the kidney, 
marked tubular injury, which was manifested as loss of brush 
border, as well as glomerular changes such as expansion of the 
mesangial matrix were observed in the IFO direct i.v. group 
as compared to those in the IV and IV+CV groups (Fig. 6A 
and B). In addition, the IFO direct i.v. group showed marked 
suppression of spermatogenesis with necrosis of the germ cells, 
while the IV and IV+CV groups showed no marked changes in 
spermatogenesis (Fig. 6C and D).
Table I. Non-viable cell population in trypan blue analysis.
Treatment Population of non-viable cells (%)
 (mean ± SD)
PBS 1.5 ±0.9
CSB 2.1±1.2
PV 3.3±1.8
CV 3.1±1.9
IFO 13±3.4a
IV 28±5.5a
IFO+CSB 25±6.7b
IV+CSB 40±9.2c
IFO+CV 75±10.8d
IV+CV 98±1.2e
aP<0.05 vs. PBS, CBS, PV and CV; bP<0.05 vs. PBS, CBS, PV, CV 
and IFO; cP<0.01 vs. IFO groups, P<0.05 vs. IV and IFO+CBS; 
dP<0.001 vs. IV+CBS, P<0.05 vs. IFO+CV.
Figure 3. Flow cytometric analyses of apoptosis using PI staining. Each 
graph shows the event count at each intensity according to the antitumor 
agent. The proportion of the population (%) of apoptotic and/or necrotic cells 
was measured as M1 and is presented in Table II.
Table II. Population of non-viable cells (M1) in flow cyto-
metric analysis.
Treatment Population of non-viable cells (%)
PV 1.6±1.1
CV 1.4±1.0
IFO 8.8±1.9a
IV 10.2±2.9a
IFO+CSB 16.5±3.9b
IV+CSB 25.2±4.2b
IFO+CV 32.8±5.9b
IV+CV 97.1±1.9c
aP<0.05 vs. PV and CV; bP<0.05 vs. PV and CV; cP<0.001 vs. PV 
and CV.
Figure 4. Trace of tumor volumes after antitumor agent administration. The 
symbols represent the mean value of each group, and the bars represent 
standard deviation.
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Fertility test. To clarify whether the DDS using Span 80 nano-
vesicles could prevent infertility, a fertility test was performed. 
The test revealed that the male mice after IV+CV administra-
tion had normal fertility, and there were no malformations in 
their progeny (data not shown).
Discussion
We present findings herein to support the evidence that the 
DDS with Span 80 vesicles can enhance the antitumor effects 
of IFO and caffeine-potentiated IFO chemotherapy, as well as 
suppress the adverse effects induced by chemotherapy. In vitro, 
IV+CV induced drastic cell death in a very early phase in 
contrast to the ‘mild’ apoptosis induction by IFO alone, IV 
alone or combinations of IFO+CSB, IV+CSB and IFO+CV. 
This suggests that the immediate delivery of IFO and CSB 
into the cytosol leads to extremely rapid apoptosis induction, 
although the detailed mechanisms are still unknown.
The DDS with nano-vesicles has been developed with 
many types of phospholipids and/or detergents (6-8,15). 
Among them, the Span 80 nano-vesicle appears to be a 
promising material due to its favorable physicochemical prop-
erties, such as membrane fluidity and flexibility. Regarding 
membrane fluidity, Span 80 vesicles were reported to have 
markedly high fluidity with various cholesterol contents as 
compared to conventional phospholipid liposomes, including 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 
liposomes. In addition to the high fluidity, Span 80 vesicles 
also have greater flexibility as compared to DPPC and POPC 
liposomes (10).
Kato et al reported that while non-vesicular aggregates 
are often observed in liposome suspensions, Span 80 vesicle 
suspensions can also include non-vesicular aggregates such 
as tubulin structures. Meanwhile, it has been reported that 
Span 80 vesicles are kinetically-trapped aggregates and not 
thermodynamic equilibrium structures, as in most vesicles 
formed from phosphatidylcholines (liposomes) (9).
IFO has been reported to induce adverse effects in the 
kidney (16-20), gonadal cells (21-23), and bone marrow along 
with other organs (24,25). In the present study, the mice in 
the IFO i.v. group also exhibited a certain degree of tubular 
injury and glomerular changes as well as severe suppression 
of spermatogenesis with gonadal cell necrosis. In contrast, 
DDS with Span 80 vesicles manifested marked suppression 
of the adverse effects in the kidney and testis. This phenom-
enon could be due to tumor selectivity of the vesicles, which 
may be partially derived from the avoidance of phagocytosis 
by macrophages based on the pegylation of the vesicles, and 
could also be from the lower permeability of vesicles at the 
blood-testis barrier as compared to the direct injection of low 
molecular weight molecules such as IFO (23,26).
Our findings suggest that the higher tumor selectivity 
of Span 80 vesicles may be associated with their pegylation 
as well as high fluidity and flexibility, which result in higher 
vascular permeability and tendency to fuse with the instable 
cell membrane of the tumors (27). Indeed, a cell fusion model 
of Span 80 vesicles has been recently reported (11). In addition, 
our data demonstrated that CV produced significantly greater 
antitumor effects as compared to the direct injection of CSB. 
This may also be due to pegylation-associated tumor selectivity 
and the tendency for cell fusion which may enable the imme-
diate delivery of caffeine into the cytoplasm. Regarding the 
selectivity of caffeine delivery, it may result in the prevention of 
caffeine toxicity which may cause the withdrawal of numerous 
patients from caffeine-potentiated chemotherapy (5).
Figure 5. Representative photomicrographs of the tumors treated with (A) 
CV, (B) IFO, (C) IV and (D) IV+CV, and the proportion of necrotic area (%) 
of each animal from each group. Center bars represent mean value, and the 
upper and lower bars represent standard deviation.
Figure 6. Representative photomicrographs of the kidney (A and B) and 
testis (C and D) from an animal treated with IV+CV (A and C) and IFO i.v. 
(B and D).
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Currently, DDS using liposomal nano-vesicles containing 
doxorubicin is applied with marked efficacy (6-8,28-30). Next 
generation liposomes, which have targeting molecules on their 
surface, have also been under development. A study of the 
anti-carcinoma application of Span 80 vesicles containing 
doxorubicin was recently reported (27). Span 80 not only has 
favorable physicochemical properties, but is also safe since 
it is already used as a stabilizer for injected drugs. In addi-
tion, Span 80 vesicles should cost drastically less than normal 
liposomes. Hence, Span 80 vesicles could be a promising next 
generation material for DDS.
In summary, the DDS with Span 80 vesicles may enhance 
the antitumor effects of IFO and of caffeine-potentiated IFO 
chemotherapy against osteosarcoma. Moreover, the usage of 
this DDS may suppress the adverse effects of chemotherapy. 
Thus, this DDS model has potential importance for clinical 
application in the therapy of metastatic osteosarcoma.
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